These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 15027061)
21. Pharmacology and immunology of botulinum toxin type A. Aoki KR Clin Dermatol; 2003; 21(6):476-80. PubMed ID: 14759579 [TBL] [Abstract][Full Text] [Related]
22. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Atassi MZ; Jankovic J; Dolimbek BZ Neurology; 2008 Sep; 71(13):1040; author reply 1040-1. PubMed ID: 18809844 [No Abstract] [Full Text] [Related]
23. The nature of neutralization reaction between effector protein and monoclonal antibody: a quantitative study of neutralization characteristics of anti-interferon antibodies. Kawade Y; Watanabe Y Immunology; 1985 Nov; 56(3):489-95. PubMed ID: 4077097 [TBL] [Abstract][Full Text] [Related]
25. Characterization of monoclonal immunoglobulin a and g against shiga toxin binding subunits produced by intranasal immunization. Tanikawa T; Ishikawa T; Maekawa T; Kuronane K; Imai Y Scand J Immunol; 2008 Oct; 68(4):414-22. PubMed ID: 18782271 [TBL] [Abstract][Full Text] [Related]
26. Discussion regarding botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications. Minimal risk of antibody formation after aesthetic treatment with type a botulinum toxin. Pickett A; Caird D Facial Plast Surg Clin North Am; 2009 Nov; 17(4):633-4; discussion 634-77, vii. PubMed ID: 19900668 [TBL] [Abstract][Full Text] [Related]
27. Immunological properties of Hn-33 purified from type A Clostridium botulinum. Sharma SK; Singh BR J Nat Toxins; 2000 Nov; 9(4):357-62. PubMed ID: 11126514 [TBL] [Abstract][Full Text] [Related]
28. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. Razai A; Garcia-Rodriguez C; Lou J; Geren IN; Forsyth CM; Robles Y; Tsai R; Smith TJ; Smith LA; Siegel RW; Feldhaus M; Marks JD J Mol Biol; 2005 Aug; 351(1):158-69. PubMed ID: 16002090 [TBL] [Abstract][Full Text] [Related]
29. A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. Lou J; Wen W; Conrad F; Meng Q; Dong J; Sun Z; Garcia-Rodriguez C; Farr-Jones S; Cheng LW; Henderson TD; Brown JL; Smith TJ; Smith LA; Cormier A; Marks JD Toxins (Basel); 2018 Feb; 10(2):. PubMed ID: 29462889 [TBL] [Abstract][Full Text] [Related]
30. The application of botulinum toxin in the prostate. Chuang YC; Chancellor MB J Urol; 2006 Dec; 176(6 Pt 1):2375-82. PubMed ID: 17085104 [TBL] [Abstract][Full Text] [Related]
31. [Recombinant design and expression of human three-domain antibody against BoNTa]. Wang H; Yin J; Shi J; Meng LL; Li PZ Wei Sheng Wu Xue Bao; 2005 Apr; 45(2):223-5. PubMed ID: 15989265 [TBL] [Abstract][Full Text] [Related]
32. Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. Diamant E; Lachmi BE; Keren A; Barnea A; Marcus H; Cohen S; David AB; Zichel R PLoS One; 2014; 9(1):e87089. PubMed ID: 24475231 [TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Kranz G; Sycha T; Voller B; Kranz GS; Schnider P; Auff E Neurology; 2008 Jan; 70(2):133-6. PubMed ID: 18180443 [TBL] [Abstract][Full Text] [Related]
34. Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments. Joshi SG; Elias M; Singh A; Al-Saleem FH; Ancharski D; Nasser Z; Takahashi T; Simpson LL Neuroscience; 2011 Apr; 179():208-22. PubMed ID: 21277940 [TBL] [Abstract][Full Text] [Related]
35. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity. Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181 [TBL] [Abstract][Full Text] [Related]
36. The basic science of botulinum toxin. Lam SM Facial Plast Surg Clin North Am; 2003 Nov; 11(4):431-8. PubMed ID: 15062246 [TBL] [Abstract][Full Text] [Related]
37. Ethyl acetate extract from black tea prevents neuromuscular blockade by botulinum neurotoxin type A in vitro. Satoh E Int J Food Sci Nutr; 2005 Dec; 56(8):543-50. PubMed ID: 16638658 [TBL] [Abstract][Full Text] [Related]
38. [Toxin-neutralizing monoclonal antibodies to the different domains of anthrax protective antigen]. Xu JJ; Zhang J; Liu SL; Lv TJ; Chen W; Li GL; Ge M; Guo Q Wei Sheng Wu Xue Bao; 2005 Dec; 45(6):947-51. PubMed ID: 16496709 [TBL] [Abstract][Full Text] [Related]
39. Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. Nagata S; Numata Y; Onda M; Ise T; Hahn Y; Lee B; Pastan I J Immunol Methods; 2004 Sep; 292(1-2):141-55. PubMed ID: 15350519 [TBL] [Abstract][Full Text] [Related]
40. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Atassi MZ; Dolimbek GS; Deitiker PR; Aoki KR; Dolimbek BZ Mol Immunol; 2005 Aug; 42(12):1509-20. PubMed ID: 15950744 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]